2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Genitourinary
1
Conditions
Obesity
3
Urologic Neoplasms
1
Stomach Neoplasms
1
Smoking
1
Sarcopenia
1
Risk Reduction Behavior
1
Rectal Neoplasms
1
Postoperative Complications
1
Patient Preference
1
Overweight
1
Motor Activity
1
Malnutrition
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Alcohol Drinking
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Adiposity
×
Clear all
NCT04088968
2024-03-22
STRONG-CS
Bispebjerg Hospital
Phase NA
Unknown
100 enrolled